14.09.2009 12:30:00

BioReference Laboratories, Inc to Speak at the UBS Global Life Sciences Conference

BioReference Laboratories, Inc (NASDAQ:BRLI) announced today that Marc D. Grodman M.D., President and Chief Executive Officer, is scheduled to speak at the 2009 UBS Global Life Sciences Conference on Monday, September 21, 2009, at The Grand Hyatt Hotel located in New York, NY. The BioReference Laboratories presentation is scheduled to begin at 8:00 a.m. Eastern Daylight Time.

Those wishing to listen to the live audio webcast may access it on the Company’s corporate web site, www.bioreference.com. Please go to the site ten minutes before the presentation is ready to begin. You will need to register as well as download and install any necessary audio software. The webcast will be archived on the BioReference website for 30 days following the call.

About BioReference Laboratories, Inc.

BRLI is the third largest full service laboratory in the United States and the largest independent regional laboratory in the Northeastern market, primarily a clinical testing lab servicing physician offices with concentrations in the focused markets of esoteric testing, molecular diagnostics, anatomical pathology and correctional health care. BRLI operates as a national oncology laboratory under its GenPath label. Better science, superior technology and better service have enabled GenPath to earn a reputation as one of the premier hematopathology laboratories in the country. BRLI’s innovative technology platform for sexually transmitted infections has enabled it to expand as a national laboratory in the area of Women’s Health. GeneDx, a wholly owned subsidiary, is the BRLI genetics laboratory and is typically recognized as the leading laboratory for testing of rare genetic diseases; GeneDx has now become a technology leader with GenomeDx, based on a CGH array platform and its NextGen sequence offerings that are currently offered in cardiology and will be offered in the future in other disease specific areas.

www.bioreference.com

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Nachrichten zu Bio-Reference Laboratories Inc Stock Settlementmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Bio-Reference Laboratories Inc Stock Settlementmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Indizes in diesem Artikel

NASDAQ Comp. 19 489,68 -1,89%